Adverum Biotechnologies (ADVM) Competitors $4.87 -0.53 (-9.81%) As of 09:47 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ADVM vs. KMDA, ALLO, ARCT, RVNC, ABVX, HUMA, AURA, RAPP, RNAC, and TSHAShould you be buying Adverum Biotechnologies stock or one of its competitors? The main competitors of Adverum Biotechnologies include Kamada (KMDA), Allogene Therapeutics (ALLO), Arcturus Therapeutics (ARCT), Revance Therapeutics (RVNC), ABIVAX Société Anonyme (ABVX), Humacyte (HUMA), Aura Biosciences (AURA), Rapport Therapeutics (RAPP), Cartesian Therapeutics (RNAC), and Taysha Gene Therapies (TSHA). These companies are all part of the "pharmaceutical products" industry. Adverum Biotechnologies vs. Kamada Allogene Therapeutics Arcturus Therapeutics Revance Therapeutics ABIVAX Société Anonyme Humacyte Aura Biosciences Rapport Therapeutics Cartesian Therapeutics Taysha Gene Therapies Kamada (NASDAQ:KMDA) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, community ranking, dividends, profitability, valuation, media sentiment and analyst recommendations. Is KMDA or ADVM more profitable? Kamada has a net margin of 9.92% compared to Adverum Biotechnologies' net margin of 0.00%. Kamada's return on equity of 6.30% beat Adverum Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Kamada9.92% 6.30% 4.49% Adverum Biotechnologies N/A -65.14%-40.52% Which has more risk and volatility, KMDA or ADVM? Kamada has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Do institutionals & insiders have more ownership in KMDA or ADVM? 20.4% of Kamada shares are owned by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are owned by institutional investors. 36.1% of Kamada shares are owned by insiders. Comparatively, 4.2% of Adverum Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in KMDA or ADVM? Adverum Biotechnologies received 43 more outperform votes than Kamada when rated by MarketBeat users. However, 66.26% of users gave Kamada an outperform vote while only 60.20% of users gave Adverum Biotechnologies an outperform vote. CompanyUnderperformOutperformKamadaOutperform Votes32666.26% Underperform Votes16633.74% Adverum BiotechnologiesOutperform Votes36960.20% Underperform Votes24439.80% Which has higher earnings & valuation, KMDA or ADVM? Kamada has higher revenue and earnings than Adverum Biotechnologies. Adverum Biotechnologies is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKamada$160.95M2.51$8.28M$0.2627.05Adverum Biotechnologies$1M101.31-$117.17M-$5.99-0.81 Does the media favor KMDA or ADVM? In the previous week, Kamada had 4 more articles in the media than Adverum Biotechnologies. MarketBeat recorded 10 mentions for Kamada and 6 mentions for Adverum Biotechnologies. Adverum Biotechnologies' average media sentiment score of 1.95 beat Kamada's score of 0.27 indicating that Adverum Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 0 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adverum Biotechnologies 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts recommend KMDA or ADVM? Kamada presently has a consensus target price of $14.67, indicating a potential upside of 108.54%. Adverum Biotechnologies has a consensus target price of $27.83, indicating a potential upside of 471.53%. Given Adverum Biotechnologies' higher probable upside, analysts plainly believe Adverum Biotechnologies is more favorable than Kamada.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kamada 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Adverum Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 SummaryKamada beats Adverum Biotechnologies on 11 of the 18 factors compared between the two stocks. Remove Ads Get Adverum Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADVM vs. The Competition Export to ExcelMetricAdverum BiotechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$100.97M$3.03B$5.68B$8.30BDividend YieldN/A1.54%4.55%4.02%P/E Ratio-0.8129.9524.6019.25Price / Sales101.31447.85388.5994.32Price / CashN/A168.6838.1634.64Price / Book0.594.227.084.46Net Income-$117.17M-$71.72M$3.19B$247.07M7 Day Performance-9.98%-3.44%-0.93%0.14%1 Month Performance16.51%-9.94%3.56%-4.39%1 Year Performance-65.58%-23.03%14.29%4.85% Adverum Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADVMAdverum Biotechnologies4.2944 of 5 stars$4.87-9.8%$27.83+471.5%-67.0%$100.97M$1M-0.81190Upcoming EarningsPositive NewsKMDAKamada3.9826 of 5 stars$6.80-5.3%$14.50+113.2%+23.6%$390.86M$160.95M24.29360Analyst DowngradeGap DownHigh Trading VolumeALLOAllogene Therapeutics2.7845 of 5 stars$1.85-4.6%$9.40+408.1%-62.7%$387.89M$22,000.00-1.19310ARCTArcturus Therapeutics2.9917 of 5 stars$14.16+0.6%$59.20+318.1%-63.3%$384.02M$138.39M-6.38180RVNCRevance Therapeutics1.9971 of 5 stars$3.65flat$8.39+129.7%N/A$381.02M$234.04M-1.89500Analyst ForecastABVXABIVAX Société Anonyme2.0234 of 5 stars$6.00+1.0%$38.67+544.4%-48.7%$380.30MN/A0.0061Analyst RevisionGap UpHigh Trading VolumeHUMAHumacyte2.0855 of 5 stars$3.01-1.0%$13.71+355.6%-8.3%$378.84M$1.57M-2.25150News CoverageGap DownAURAAura Biosciences2.6776 of 5 stars$7.54+2.6%$23.00+205.0%-10.4%$376.63MN/A-4.3650Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeRAPPRapport Therapeutics1.7127 of 5 stars$10.18-3.1%$35.00+243.8%N/A$371.53MN/A-0.74N/ARNACCartesian Therapeutics2.1256 of 5 stars$14.44-8.6%$42.14+191.8%-22.0%$366.99M$47.94M-0.2764Positive NewsTSHATaysha Gene Therapies2.1084 of 5 stars$1.79+4.1%$6.63+270.1%-42.2%$366.95M$8.33M2.84180Positive News Remove Ads Related Companies and Tools Related Companies KMDA Alternatives ALLO Alternatives ARCT Alternatives RVNC Alternatives ABVX Alternatives HUMA Alternatives AURA Alternatives RAPP Alternatives RNAC Alternatives TSHA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADVM) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adverum Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
